JB Chemicals passes USFDA inspection with one observation

JB Chemicals and Pharmaceuticals said its Gujarat unit has passed the US health regulator's periodical inspection with one minor procedural observation.

501
USFDA Inspection
USFDA Inspection

Last Updated on October 17, 2024 by The Health Master

NEW DELHI: JB Chemicals and Pharmaceuticals said its Gujarat unit has passed the US health regulator’s periodical inspection with one minor procedural observation.

The company’s solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat, has successfully passed periodical inspection by USFDA with one minor procedural observation, JB Chemicals and Pharmaceuticals said in a filing to BSE.

This observation does not impact continuity of the business and the company would continue its manufacturing activities in current good manufacturing practice (cGMP) compliant manner, it said.

Also read: USFDA’s inspection of Divis Lab: zero observations

The company proposes to address this observation in the next 15 days.

“The said inspection was carried-out from February 3, 2020 to February 7, 2020,” as per the filing.

Shares of the company were trading at Rs 556.00 apiece on BSE, down 0.91 per cent from the previous close.